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Studies examining associations between purine metabolites and type 2 diabetes (T2D) are limited. 
We prospectively examined associations between plasma levels of purine metabolites with T2D risk 
and the modifying effects of transcription factor-7-like-2 (TCF7L2) rs7903146 polymorphism on these 
associations. This is a case-cohort design study within the PREDIMED study, with 251 incident T2D 
cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D 
at baseline (median follow-up: 3.8 years). Metabolites were semi-quantitatively profiled with LC-MS/
MS. Cox regression analysis revealed that high plasma allantoin levels, including allantoin-to-uric 
acid ratio and high xanthine-to-hypoxanthine ratio were inversely and positively associated with T2D 
risk, respectively, independently of classical risk factors. Elevated plasma xanthine and inosine levels 
were associated with a higher T2D risk in homozygous carriers of the TCF7L2-rs7903146 T-allele. The 
potential mechanisms linking the aforementioned purine metabolites and T2D risk must be also further 
investigated.
Purines are constituent parts of nucleotides and nucleic acids, playing several roles in human physiology, affecting 
tissue function, cell integrity, and oxidation. In catabolism, their monophosphate forms are converted to ino-
sine and guanosine; purine nucleoside phosphorylase converts them to hypoxanthine and guanine, respectively. 
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Xanthine oxidase (XO), and guanine deaminase, convert them to xanthine. Finally, xanthine is again oxidized by 
XO to uric acid1.
Blood levels of uric acid are well regulated in healthy subjects but when hyperuricemia occurs, its chronicity 
has been associated with gout, muscular pain, cardiovascular or/and renal disease and type 2 diabetes (T2D)2. 
Concerning other purine metabolites, elevated plasma allantoin concentrations (8-fold higher) were reported in 
patients with diabetes, compared to healthy controls3, indicating an increased oxidative stress in this metabolic 
condition. In addition, studies in erythrocytes of patients with diabetes4 indicated increased adenine and gua-
nine de-phosphorylation, as well as increased adenosine, inosine, guanosine, and hypoxanthine concentrations, 
together with a higher turnover ratio of nucleotides and hyper-metabolism, when compared to that in healthy 
subjects.
In regard to the enzymes involved, compared to healthy controls, serum XO activity was found increased 
in patients with T2D5. Similarly, in patients with metabolic syndrome, XO activity was increased and associ-
ated with inflammatory or oxidative status markers6. In addition, the activity of adenosine deaminase (ADA), 
an enzyme that converts adenosine into inosine, was found increased significantly in T2D patients, correlat-
ing positively with blood glucose levels7. Since adenosine increases glucose uptake into cells, its deamination in 
insulin-sensitive tissues may be considered a homeostatic cell-protecting adaptation8.
Studies that examine cross-sectional or/and longitudinal associations among peripheral levels of uric acid and 
other purine metabolites, diabetes risk factors, and diabetes incidence are limited9. Likewise, although the tran-
scription factor-7-like-2 (TCF7L2) rs7903146 polymorphism is one of the main genes associated with increased 
T2D risk, its interactions with purine metabolites overall10, or involvement in genetically linking T2D with gout 
development11, remain unknown. Therefore, in the present prospective study, nested in the framework of the 
PREDIMED trial, we examined associations between plasma levels of purine-catabolism metabolites or relevant 
ratios (precursor-product) and T2D risk. Furthermore, we examined whether the TCF7L2-rs7903146 polymor-
phism modifies these associations.
Methods
Study design and population. This study was nested, as an unstratified case-cohort study, within the 
PREDIMED study (ISRCTN35739639), a cardiovascular primary-prevention trial conducted in Spanish primary 
healthcare centers. The methods and design of the PREDIMED trial has been described in detail elsewhere12. The 
present case-cohort study comprises a random selection of 694 non-diabetic participants (approximately 20%) 
from the eligible subjects of the PREDIMED cohort without T2D at study inception (3,541 participants were free 
of T2D at baseline) and with available blood samples, together with all incident cases of T2D that occurred during 
the follow-up with available plasma samples (251 out of the 273 incident cases). Of the 892 participants included 
in our analyses, 641 were in the sub-cohort (including 53 overlapping cases) and 198 were the rest of the T2D 
incident cases, giving a total of 251 cases (Supplemental Fig. 1). Of these, 686 participants out of the 892 had avail-
able samples after 1-year of follow-up and were included in the 1-year changes analyses (Supplemental Fig. 1). The 
Research Ethics Committees (RECs) for each of the recruitment centers approved the study protocol, and partici-
pants provided written informed consent. All analyses were performed in accordance with the relevant guidelines 
and regulations. The RECs were: del Hospital Clinic de Barcelona, del Hospital Universitari Sant Joan de Reus, 
de la universidad de Valencia, de la Universidad de Navarra, de la Facultad de Medicina, de la Universidad de 
Málaga, de Euskadi, del Complejo Hospitalario Universitario Insular- Materno Infantil (CHUIMI) del Servicio 
Canario de Salud, Las Palmas de Gran Canaria, del Parc de Salut Mar, de les Balearic Islands.
Study samples and metabolite profiling. Fasting (for ≥8 hours) plasma EDTA samples (baseline 
and at the end of 1-year of follow-up) were collected from subjects and stored at −80 °C. In June 2015, pairs 
of samples for each participant were randomly ordered and shipped on dry ice to the Broad Institute (Boston, 
Massachusets, USA) for metabolomics assays. Metabolites related to purine catabolism, including uric acid, allan-
toin, xanthine, hypoxanthine, inosine, adenosine and guanosine, were semi-quantitatively profiled using liquid 
chromatography-tandem mass spectrometry (LC-MS) on a system comprised of a Shimadzu Nexera X2 U-HPLC 
(Shimadzu Corp., Marlborough, MA, USA), coupled to a Q Exactive hybrid quadrupoleorbitrap mass spectrom-
eter (Thermo Fisher Scientific)13. Metabolite identities were confirmed using authentic reference standards. 
Raw data were processed using TraceFinder software (Thermo Fisher Scientific) and Progenesis QI (Nonlinear 
Dynamics; Newcastle upon Tyne, UK).
DNA Extraction and Genotyping. Genomic DNA was extracted from buffy-coat and the 
TCF7L2-rs7903146 was genotyped in the whole cohort on a 7900 HT Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) using a fluorescent allelic discrimination TaqManTM assay as previously 
described14.
Ascertainment of T2D cases. T2D was a pre-specified secondary endpoint of the PREDIMED trial and 
it was identified by clinical diagnosis and/or use of antidiabetic medication. Information was collected through 
contact with participants and primary health care physicians, annual follow-up visits, yearly ad-hoc reviews of 
medical charts and annual consultation of the National Death Index, as it has been described elsewhere15. The 
American Diabetes Association criteria16, namely two confirmations of fasting plasma glucose ≥7.0 mmol/L or 
2-h plasma glucose ≥11.1 mmol/L, after a 75-g oral glucose load were used to adjudicate incident cases.
Assessment of covariates and other variables. At baseline and at yearly follow-up visits, a 47-item 
questionnaire about lifestyle variables, smoking status, medical history and medication use was administered. 
Physical activity was assessed using a validated Spanish version of the Minnesota Leisure Time Physical Activity 
Questionnaire17. To assess the degree of adherence to Mediterranean diet (MedDiet), a 14-item validated 
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questionnaire was filled in for each participant18. Body mass index (BMI) was calculated as weight divided by 
height squared (kg/m2). Participants’ triacylglycerol (TAG), total cholesterol, high-density lipoprotein (HDL) and 
low-density lipoprotein (LDL) levels were measured using fasting plasma at baseline. Blood glucose and insulin 
levels were centrally assessed at baseline and at the end of 1-year of follow-up. Insulin resistance was estimated 
by the HOMA method using the following equation: HOMA-IR was calculated using the following equation: 
HOMA-IR = [fasting insulin (μIU/mL) × fasting glucose (mmol/L)]/22.5.
Statistical analysis. Baseline characteristics of cases and non-cases were described as means and standard 
deviations (SD) for quantitative variables, and percentages or numbers for categorical variables. We applied a 
natural logarithmic transformation to approximate a normal distribution of metabolites levels. We also examined 
product-to-precursor ratios of metabolites, as described in the pathway of purine catabolism, as a metabolite 
trait (by dividing the raw values and then taking natural logarithmic transformations). Person-time of follow-up 
was calculated as the interval between the randomization date and date of T2D event, death, or date of the last 
contact, whichever came first. We used Cox proportional hazard models, with Barlow weights (to account for 
the over-representation of cases), to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs) for 
risk of T2D. A crude model and two multivariable-adjusted Cox regression models were fitted as follows: a) 
multivariable model 1 (MV1), adjusted for age (years), sex (male, female), body mass index (kg/m2), intervention 
group and baseline fasting glucose (mg/dl) (adding a quadratic term to account for the departure from linearity; 
b) MV2, additionally adjusted for the TCF7L2-rs7903146 polymorphism (assuming an additive genetic model), 
smoking (never, current, former), leisure-time physical activity (metabolic equivalent tasks in minutes/day), 
baseline dyslipidaemia (yes/no), and hypertension (yes/no). We stratified the models according to recruitment 
center. Baseline metabolites levels and their ratios were analysed as both continuous variables (1-SD increment 
in their transformed levels) and using quartiles (using cut-points defined among non-cases). To appraise the 
linear trend across quartiles, the median metabolites levels and their ratios within each quartile was included 
in the Cox regression models as a continuous variable. To account for multiple testing, we adjusted p-values of 
the multivariable adjusted associations between quartiles or 1-SD increment in metabolites levels and T2D risk, 
using Benjamin-Hochberg false discovery rate (FDR) procedure19. A FDR-p-value < 0.05 was considered to be 
statistically significant. We also examined the associations of 1-year changes in metabolites and their ratios with 
T2D risk. We used the same models as in the baseline analyses but further adjusted for baseline metabolites levels 
or their ratios. With respect to metabolites or their ratios, we first calculated the ratio between 1-year and baseline 
levels and then normalized this ratio with the natural logarithmic transformation. To test the robustness of our 
findings we conducted one sensitivity analysis on the associations of baseline metabolites or their ratios with risk 
for T2D by including two variables (HDL and TAG) in the multivariable model 2 that were significantly different 
between cases and non-cases, leaving 71 incident cases due to the high percentage of missing values (HDL: 41%, 
TAG: 33%). To examine whether the aforementioned genotypes modified the association between metabolites or 
relevant ratios and T2D incidence, interactions were tested by including a multiplicative interaction term (metab-
olite x TCF7L2-rs7903146 genotypes) or (ratio x TCF7L2-rs7903146 genotypes) and also a TCF7L2-rs7903146 
genotypes main effect in the MV2. Stratified analyses by TCF7L2-rs7903146 genotypes were also carried out 
assuming an additive genetic model. The associations were adjusted for multiple testing as described above. We 
also estimated the joint association of plasma metabolites levels and rs7903146 polymorphisms (TT or CC gen-
otypes) with T2D. We considered as the reference group those participants with CC genotype and metabolites 
levels (lower than the median). Statistical analyses were performed using Stata 13.1 (Stata Corp., College Station, 
Texas, USA). A two-sided p value less than 0.05 was considered significant.
Results
Participants’ characteristics. The median follow-up of the study population was 3.8 years. A total of 251 
incident cases and 641 control participants were included in the study. Participants’ characteristics are summa-
rized in Table 1. The mean age of participants at baseline was 66.5 years and the mean BMI was 30.1 (3.5) kg/m2. 
Briefly, a higher proportion of incident cases were men and current smokers compared to non-cases. As com-
pared with non-cases, those participants who developed T2D were also more likely to have a higher prevalence of 
hypertension and dyslipidaemia in addition to higher BMI, fasting glucose and triacylglycerol levels while lower 
HDL cholesterol levels (Table 1).
Associations of baseline metabolites and relevant ratios (precursor-product) with risk for 
T2D. Table 2 shows the associations of baseline levels of individual metabolites and relevant ratios with 
T2D risk. In fully-adjusted model (MV2), allantoin when modelled as quartile, was significantly associated 
with lower T2D risk [HR in the highest versus lowest quartile was 0.44 (95% CI 0.25–0.80). Regarding ratios 
of allantoin-to-uric acid and xanthine-to-hypoxanthine, the estimated HR for incident T2D in the highest ver-
sus lowest quartile was 0.42 (95% CI 0.22–0.82) and 2.53 (95% CI 1.40–4.58), respectively. These associations 
remained significant after accounting for multiple comparisons. There were no significant associations between 
other baseline metabolites or ratios and incident T2D, either they were modelled continuously (per 1 SD) or as 
quartiles.
One year changes in levels of metabolites, relevant ratios (precursor-product) and risk of 
T2D. Associations between 1-year changes in metabolites levels and relevant ratios across quartiles with the 
risk of T2D are shown in Supplemental Table 1. In the highest quartile of increase in inosine-to-adenosine and 
xanthine-to-guanosine ratio a significant inverse association with T2D risk was found, with HR 0.43 (95% CI 
0.19–0.95), and HR 0.42 (95% CI 0.20–0.88), respectively. We repeated the analyses using 1-SD increment in 
1-year changes of metabolite levels and relevant ratios and found that per 1-SD increase in xanthine-to-guanosine 
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ratio, the risk of T2D was associated with a decrease of 22%, with HR 0.78 (95% CI 0.62–0.98) (Supplemental 
Table 2). After adjusting for multiple testing, none of these associations remained statistically significant.
Sensitivity analysis. Supplemental Table 3 shows the associations of baseline levels of individual metabo-
lites and relevant ratios with T2D risk after including HDL cholesterol and TAG in the fully adjusted model. The 
associations between allantoin and allantoin-to-uric acid ratio with T2D risk remained significant.
Spearman’s correlation analysis. The correlations between baseline metabolites, relevant ratios and base-
line HOMA-IR are presented in Table 3. Several metabolites including uric acid, guanosine, xanthine and aden-
osine were found to be positively correlated with HOMA-IR (p < 0.05). The ratio of xanthine-to-hypoxanthine 
was also positively correlated with HOMA-IR (r = 0.09, p = 0.015). On the other hand, inosine-to-adenosine 
and allantoin-to-uric acid ratios were negatively correlated with HOMA-IR (r = −0.09, p = 0.013; r = −0.07, 
p = 0.037). Correlation analysis between 1-year changes in levels of metabolites, relevant ratios and 1-year changes 
in HOMA-IR (increase in HOMA-IR levels) revealed significant positive correlations for uric acid (r = 0.14, 
p = 0.001), allantoin (r = 0.09, p = 0.026), guanosine (r = 0.13, p = 0.002) and xanthine-to-hypoxanthine ratio 
(r = 0.10, p = 0.024).
Interaction between the TCF7L2-rs7903146 polymorphism and metabolites on T2D risk. As 
expected, TT individuals had a higher risk for T2D compared with CC homozygotes, with HR 2.03 (95% CI 
1.12–3.70), p = 0.020, after controlling for several potential confounding factors. No excess risk was conferred 
by the heterozygous genotype [CT vs. CC: HR 1.19 (95% CI 0.79–1.79), p = 0.387]. We found statistically sig-
nificant interactions between metabolites levels, a relevant ratio and the TCF7L2-rs7903146 polymorphism in 
determining T2D risk in an additive model (Table 4). We found that per 1-SD increase in plasma xanthine and 
inosine levels, the risk of T2D significantly increased in TT individuals, with HR 2.34 (95% CI 1.23–4.45), and 
HR 3.09 (95% CI 1.23–7.73), respectively. On the other hand, per 1-SD increase in hypoxanthine-to-inosine ratio, 
a 74% lower risk of T2D was found in TT subjects [HR 0.26 (95% CI 0.10–0.70)]. After adjustment for multiple 
comparisons the associations between these metabolites, the ratio and T2D risk remained statistically significant. 
When the joint effects were examined, individuals with TT genotype and plasma xanthine levels above/equal to 
the median value had significantly higher risk of T2D [HR 2.64 (95% CI 1.02–6.83)] than those with CC genotype 
and xanthine levels below the median (reference) (Fig. 1a). Similarly, higher risk was found in TT individuals 
when levels of inosine were higher or equal to the median [HR 2.65 (95% CI 1.05–6.69)] (Fig. 1b). The levels of 
the aforementioned metabolites did not significantly differ across the genotypes in the additive model.
Total Cases Non-cases p value
n 892 251 641
Age (years) 66.5 (5.7) 66.4 (5.7) 66.5 (5.7) 0.781
Sex (% Women) 61.2 55.0 63.6 0.017
Body mass index, kg/m2 30.1 (3.5) 30.8 (3.3) 29.8 (3.6) <0.001
Physical activity, METs/d 240.7 (234.6) 249.2 (233.5) 237.4 (235.1) 0.500
Intervention group, %
MedDiet + EVOO 30.6 29.9 30.9 0.425
MedDiet + Nuts 36.3 37.2 33.8
Control group 33.1 36.3 31.8
Hypertension, % 91.7 96.0 90.0 0.003
Dyslipidaemia, % 84.3 79.7 86.1 0.018
Smoking, %
Never 59.0 52.6 61.5 0.006
Former 22.4 22.3 22.5
Current 18.6 25.1 16.0
Score for adherence to 
Mediterranean dieta 8.5 (2.0) 8.4 (2.0) 8.6 (1.9) 0.186
Fasting blood glucose, mg/dl 103.3 (17.6) 118.6 (18.0) 97.8 (13.8) <0.001
Total cholesterol, mg/dl 222.2 (39.3) 221.7 (42.3) 222.4 (38.1) 0.846
HDL cholesterol, mg/dL 54.7 (13.0) 52.6 (12.7) 55.7 (13.1) 0.014
LDL cholesterol, mg/dL 139.7 (32.9) 137.0 (31.6) 141.0 (33.3) 0.201
Triacylglycerol, mg/dL 140.1 (85.0) 169.0 (121.0) 128.6 (62.0) <0.001
Table 1. Baseline characteristics of the study population. Data are mean (SD) or percentage. aThis score is based 
on the 14-item dietary screener. The x2 test was used for comparison of categorical variables and Student’s t-test 
was used for comparison of continuous variables. MedDiet, Mediterranean diet; EVOO, Extra-virgin olive oil; 
MET, metabolic equivalent, HDL, high-density lipoprotein; LDL, low-density lipoprotein.
5Scientific RepoRts |          (2019) 9:2892  | https://doi.org/10.1038/s41598-019-39441-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Quartiles of plasma metabolite levels
Metabolite Q1 Q2 Q3 Q4 p trend
FDR-Adjusted  
p value (Q4 vs. Q1)
HR per 1 SD 
increment p value
FDR-Adjusted  
p value
Uric Acid
Cases 47 60 58 85
Crude model Ref. 1.18 (0.73, 1.91) 1.01 (0.62, 1.64) 1.55 (0.98, 2.45) 0.091 1.16 (0.97, 1.38) 0.098
MV1 Ref. 1.20 (0.70, 2.05) 0.97 (0.54, 1.74) 1.35 (0.78, 2.35) 0.373 1.09 (0.90, 1.31) 0.363
MV2 Ref. 1.20 (0.68, 2.11) 0.94 (0.52, 1.71) 1.36 (0.77, 2.40) 0.412 0.637 1.08 (0.88, 1.31) 0.446 0.559
Allantoin
Cases 72 63 72 43
Crude model Ref. 0.65 (0.42, 1.02) 0.89 (0.58, 1.37) 0.60 (0.36, 1.01) 0.142 0.97 (0.83, 1.15) 0.787
MV1 Ref. 0.70 (0.44, 1.13) 0.79 (0.49, 1.28) 0.48 (0.27, 0.85) 0.020 0.89 (0.75, 1.06) 0.193
MV2 Ref. 0.66 (0.40, 1.08) 0.73 (0.44, 1.22) 0.44 (0.25, 0.80) 0.011 0.045 0.86 (0.73, 1.02) 0.094 0.407
Xanthine
Cases 56 60 64 69
Crude model Ref. 1.09 (0.68, 1.76) 1.17 (0.72, 1.90) 1.47 (0.91, 2.37) 0.095 1.21 (1.04, 1.41) 0.015
MV1 Ref. 1.23 (0.73, 2.07) 1.19 (0.71, 2.00) 1.07 (0.61, 1.88) 0.901 1.08 (0.89, 1.33) 0.408
MV2 Ref. 1.15 (0.67, 1.99) 1.22 (0.71, 2.09) 1.04 (0.58, 1.87) 0.929 0.886 1.13 (0.92, 1.38) 0.243 0.451
Hypoxanthine
Cases 61 77 55 57
Crude model Ref. 1.33 (0.86, 2.06) 0.93 (0.58, 1.48) 1.02 (0.63, 1.66) 0.738 1.00 (0.83, 1.20) 0.977
MV1 Ref. 1.44 (0.91, 2.29) 0.93 (0.55, 1.57) 0.85 (0.49, 1.47) 0.296 0.93 (0.76, 1.13) 0.472
MV2 Ref. 1.30 (0.80, 2.11) 0.82 (0.48, 1.42) 0.75 (0.42, 1.33) 0.145 0.637 0.89 (0.72, 1.10) 0.280 0.455
Inosine
Cases 67 48 75 56
Crude model Ref. 0.73 (0.45, 1.18) 1.02 (0.65, 1.62) 1.02 (0.62, 1.68) 0.613 1.11 (0.91 1.34) 0.286
MV1 Ref. 0.73 (0.42, 1.27) 0.90 (0.54, 1.48) 0.92 (0.54, 1.57) 0.995 1.06 (0.86, 1.31) 0.542
MV2 Ref. 0.75 (0.42, 1.33) 0.98 (0.58, 1.63) 0.89 (0.50, 1.58) 0.939 0.798 1.05 (0.84, 1.31) 0.646 0.699
Adenosine
Cases 42 62 82 62
Crude model Ref. 1.06 (0.64, 1.76) 1.35 (0.84, 2.19) 0.90 (0.54, 1.48) 0.774 1.03 (0.88, 1.21) 0.700
MV1 Ref. 0.98 (0.56, 1.71) 1.34 (0.80, 2.25) 0.72 (0.40, 1.31) 0.374 0.89 (0.72, 1.09) 0.275
MV2 Ref. 0.88 (0.50, 1.55) 1.21 (0.72, 2.05) 0.64 (0.34, 1.19) 0.224 0.516 0.85 (0.68, 1.06) 0.162 0.451
Guanosine
Cases 44 57 71 77
Crude model Ref. 0.92 (0.56, 1.51) 1.04 (0.64, 1.69) 1.15 (0.71, 1.88) 0.461 1.00 (0.80, 1.24) 0.992
MV1 Ref. 0.93 (0.51, 1.70) 1.09 (0.60, 1.95) 1.22 (0.67, 2.22) 0.412 1.12 (0.88, 1.42) 0.361
MV2 Ref. 0.95 (0.50, 1.78) 1.06 (0.58, 1.94) 1.34 (0.73, 2.46) 0.281 0.637 1.17 (0.89, 1.54) 0.239 0.451
Ratio of metabolites
Inosine-to-Adenosine Ratio
Cases 54 61 44 58
Crude model Ref. 1.04 (0.64, 1.68) 0.79 (0.47, 1.32) 1.04 (0.62, 1.76) 0.821 0.84 (0.68, 1.03) 0.104
MV1 Ref. 1.13 (0.66, 1.92) 0.95 (0.55, 1.64) 1.15 (0.65, 2.02) 0.761 0.86 (0.68, 1.09) 0.221
MV2 Ref. 1.17 (0.66, 2.07) 0.93 (0.51, 1.70) 1.20 (0.66, 2.21) 0.712 0.787 0.89 (0.71, 1.13) 0.349 0.504
Uric Acid-to-Xanthine Ratio
Cases 56 59 71 65
Crude model Ref. 0.74 (0.47, 1.17) 0.91 (0.57, 1.45) 0.83 (0.52, 1.31) 0.586 0.88 (0.74, 1.05) 0.161
MV1 Ref. 0.94 (0.53, 1.66) 1.13 (0.67, 1.89) 0.99 (0.58, 1.70) 0.886 0.96 (0.77, 1.19) 0.706
MV2 Ref. 0.87 (0.49, 1.56) 1.16 (0.68, 1.98) 0.83 (0.47, 1.47) 0.731 0.787 0.92 (0.73, 1.15) 0.473 0.559
Allantoin-to-Uric Acid Ratio
Cases 73 70 69 37
Crude model Ref. 0.78 (0.50, 1.20) 0.79 (0.52, 1.22) 0.57 (0.33, 0.98) 0.052 0.91 (0.78, 1.07) 0.283
MV1 Ref. 0.77 (0.48, 1.25) 0.89 (0.56, 1.42) 0.43 (0.22, 0.82) 0.023 0.85 (0.72, 1.01) 0.074
MV2 Ref. 0.77 (0.46, 1.27) 0.91 (0.57, 1.45) 0.42 (0.22, 0.82) 0.023 0.047 0.84 (0.71, 0.98) 0.035 0.234
Xanthine-to-Guanosine Ratio
Cases 62 54 77 55
Crude model Ref. 0.97 (0.61, 1.57) 1.31 (0.84, 2.06) 1.42 (0.88, 2.30) 0.077 1.22 (1.04, 1.43) 0.013
Continued
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Discussion
In the present case-cohort design study within the PREDIMED trial, after adjusting for recognized T2D 
risk-factors and multiple testing, we found inverse and positive associations between high baseline levels of 
allantoin, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine ratio with T2D risk, respec-
tively. We also found that elevated plasma xanthine and inosine levels were associated with a higher T2D risk 
in individuals with TT alleles on rs7903146. This is the first time, as far as we know10,11, that this genetic variant 
of the TCF7L2 gene, which mediates high susceptibility to T2D, is reported to interact with purine-catabolism 
metabolites.
Allantoin is produced from the non-enzymatic oxidation of uric acid (Fig. 2) in humans and is considered to 
be a specific biomarker of oxidative stress3,20. We found that higher allantoin levels were associated with lower risk 
of T2D incidence as was the allantoin-to-uric acid ratio. This ratio was also negatively correlated with HOMA-IR 
at baseline. Our results are in accordance with the literature. When administered through injection, allantoin 
decreased blood glucose levels and increased blood insulin in a dose-dependent manner, in normal rats21. 
Allantoin has also been found to lower plasma glucose in diabetic rats by activating imidazoline-receptors I2 or 
I321, which improve insulin action. Furthermore, in diabetic rats, allantoin offered through diet had antidiabetic 
effects by modulating antioxidant activities and lipid profiles, promoting glucagon-like peptide-1 (GLP-1) release, 
thereby facilitating β-cells to maintain insulin and glucose levels22. Finally, in a cohort study, allantoin measured 
in urine of humans was also inversely associated with the risk of T2D20.
Uric acid is the end product of purine metabolism in humans. In our study, plasma uric acid was not associ-
ated with future risk of T2D, but correlated positively both with HOMA-IR at baseline and at 1-year follow-up. 
The causal association between serum uric acid levels and T2D remains controversial23. Uric acid is generally 
considered to be a feature of hyperinsulinemia or/and insulin resistance23; however, in patients with diabetes, its 
level may be low, due to increased urate clearance that can be associated with glycosuria, increased sodium (Na) 
secretion, and overall decreased metabolic control24.
Uric acid can be produced from xanthine via the enzymatic action of XO, which also participates in the conver-
sion of hypoxanthine-to-xanthine (Fig. 2). In our study, baseline xanthine levels and xanthine-to-hypoxanthine 
ratio were correlated with higher HOMA-IR levels. In addition, we found that this ratio was associated with 
increased risk of T2D. An increase in this ratio may reflect higher XO activity, which is involved in free radical 
production25 and has been found, increased in T2D patients5. Whether xanthine production from hypoxanthine, 
plays a role in T2D development due to increased XO activity or due to xanthine production in parallel with the 
consequent decrease in hypoxanthine, requires further investigation.
In the present study, guanosine was also positively correlated to HOMA-IR. Cyclic Guanosine monophos-
phate (cGMP) is a second messenger that mediates incretin effects; potentiates glucose-stimulated insulin secre-
tion; promotes proper beta-cells differentiation, and prevents beta-cells apoptosis, cooperating with biotin26. In 
addition, cGMP is involved in various signal-transduction pathways, mediating messages of insulin itself27. The 
interactions between the extracellular and intracellular guanosine metabolites, or/and the possible modulations 
of the latter in T2D, remain an open issue.
Quartiles of plasma metabolite levels
Metabolite Q1 Q2 Q3 Q4 p trend
FDR-Adjusted  
p value (Q4 vs. Q1)
HR per 1 SD 
increment p value
FDR-Adjusted  
p value
MV1 Ref. 0.96 (0.58, 1.60) 1.16 (0.71, 1.91) 0.87 (0.49, 1.55) 0.762 1.02 (0.84, 1.25) 0.803
MV2 Ref. 0.98 (0.58, 1.66) 1.22 (0.72, 2.06) 0.87 (0.48, 1.58) 0.742 0.798 1.03 (0.84, 1.29) 0.727 0.727
Xanthine-to-Hypoxanthine Ratio
Cases 43 70 57 80
Crude model Ref. 1.21 (0.75, 1.96) 1.06 (0.64, 1.76) 1.86 (1.14, 3.02) 0.290 1.21 (1.03, 1.42) 0.017
MV1 Ref. 1.01 (0.59, 1.72) 1.07 (0.61, 1.91) 1.84 (1.08, 3.15) 0.095 1.14 (0.95, 1.38) 0.157
MV2 Ref. 1.16 (0.65, 2.07) 1.32 (0.70, 2.47) 2.53 (1.40, 4.58) 0.085 0.026 1.23 (1.01, 1.50) 0.036 0.234
Hypoxanthine-to-Inosine Ratio
Cases 72 57 54 66
Crude model Ref. 0.61 (0.39, 0.96) 0.63 (0.39, 1.01) 0.77 (0.48, 1.24) 0.301 0.89 (0.73, 1.08) 0.244
MV1 Ref. 0.68 (0.42, 1.10) 0.58 (0.33, 1.00) 0.93 (0.56, 1.55) 0.561 0.87 (0.70, 1.08) 0.212
MV2 Ref. 0.69 (0.41, 1.13) 0.63 (0.35, 1.11) 0.91 (0.53, 1.55) 0.552 0.798 0.86 (0.69, 1.08) 0.201 0.451
Table 2. Associations of baseline individual metabolites levels and relevant ratios (precursor-product) with the 
risk of type 2 diabetes in the PREDIMED study, 2003–2010. Overall group. Abbreviations: MV, multivariable 
model; SD, standard deviation. A natural logarithmic transformation was applied to the raw value of individual 
metabolites. In the case of ratios of metabolites characterised by a precursor-product relationship, their raw 
values underwent natural logarithmic transformation. Cox regression analysis. MV1: Adjusted for age (years), 
sex (male, female), body mass index (kg/m2), intervention group (MedDiet + EVOO, MedDiet + nuts) and 
baseline fasting glucose (mg/dl) (centered on the sample mean and adding quadratic term). MV2: additionally 
adjusted for TCF7L2-rs7903146 genotype (assuming an additive genetic model), smoking (never, current, 
former), leisure-time physical activity (metabolic equivalent tasks in minutes/day), dyslipidemia and 
hypertension. False discovery rate (FDR) controlling adjustments were conducted by applying the method of 
Benjamini and Hochberg. MV, multivariable model.
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Inosine, a precursor of xanthine that was not associated to diabetes incidence in the overall population of our 
study, has notable anti-inflammatory effects, which may be mediated, at least in part, by activation of the aden-
osine A2a receptor28. Both, adenosine and inosine have been suggested to play a protective role against diabetes 
development28. We observed that inosine-to-adenosine ratio was negatively correlated with baseline HOMA-IR. 
A working hypothesis is that the production of inosine is more favourable in improving glucose homeostasis, as 
compared to adenosine.
The TCF7L2-rs7903146 polymorphism is one of the strongest and most widely replicated locus associated 
with T2D29, with the homozygous individuals (TT) being those who present a higher prevalence and fasting 
Spearman r p value
Uric Acid 0.22 <0.001
Allantoin 0.01 0.682
Xanthine 0.13 0.001
Hypoxanthine 0.02 0.644
Inosine 0.01 0.719
Adenosine 0.11 0.003
Guanosine 0.16 <0.001
Inosine-to-Adenosine −0.09 0.013
Uric Acid-to-Xanthine 0.04 0.214
Allantoin-to-Uric Acid −0.07 0.037
Xanthine-to-Guanosine 0.04 0.266
Xanthine-to-Hypoxanthine 0.09 0.015
Hypoxanthine-to-Inosine 0.01 0.821
Table 3. Spearman’s correlation analysis between baseline metabolites levels, relevant ratios and baseline 
HOMA-IR.
CC CT TT
FDR-Adjusted 
p value* p interaction
n 382 383 104
Cases, n 106 103 35
Per SD of change HR (95% CI) HR (95% CI) HR (95% CI)
Metabolite
Uric Acid 1.08 (0.82, 1.42) 0.97 (0.71, 1.32) 1.35 (0.48, 3.84) 0.668 0.540
Allantoin 0.92 (0.73, 1.15) 0.92 (0.63, 1.34) 0.74 (0.58, 0.93) 0.026 0.581
Xanthine 1.01 (0.73, 1.40) 1.37 (0.99, 1.89) 2.34 (1.23, 4.45) 0.026 0.009
Hypoxanthine 0.95 (0.69, 1.31) 0.83 (0.59, 1.17) 1.23 (0.29, 5.27) 0.842 0.238
Inosine 0.89 (0.61, 1.28) 1.05 (0.78, 1.41) 3.09 (1.23, 7.73) 0.029 0.009
Adenosine 0.95 (0.71, 1.27) 0.70 (0.47, 1.03) 0.32 (0.04, 2.62) 0.371 0.190
Guanosine 0.97 (0.78, 1.20) 1.75 (1.07, 2.87) 1.02 (0.26, 3.92) 0.978 <0.001
Ratio of metabolites
Inosine-to-Adenosine Ratio 0.99 (0.71, 1.39) 0.87 (0.58, 1.30) 0.33 (0.14, 0.78) 0.026 0.083
Uric Acid-to-Xanthine Ratio 1.04 (0.70, 1.55) 0.74 (0.54, 1.02) 0.46 (0.19, 1.14) 0.135 0.032
Allantoin-to-Uric Acid Ratio 0.87 (0.69, 1.11) 0.94 (0.64, 1.38) 0.74 (0.57, 0.95) 0.032 0.520
Xanthine-to-Guanosine Ratio 1.04 (0.76, 1.42) 1.03 (0.69, 1.52) 2.91 (1.42, 5.97) 0.026 0.068
Xanthine-to-Hypoxanthine Ratio 1.05 (0.76, 1.46) 1.55 (1.12, 2.14) 2.84 (1.26, 6.38) 0.026 0.372
Hypoxanthine-to-Inosine Ratio 1.15 (0.78, 1.71) 0.83 (0.62, 1.11) 0.26 (0.10, 0.70) 0.026 0.004
Table 4. Associations of baseline individual metabolites levels and relevant ratios (precursor-product) with the 
risk of type 2 diabetes by transcription factor-7-like 2 (TCF7L2) rs7903146 genotype (additive model: TT & CT 
& CC). Product (TCF7L2 × metabolite or ratio) interaction term was included into the model. The PREDIMED 
study, 2003–2010. Abbreviations: SD, standard deviation. aA natural logarithmic transformation was applied to 
the raw values individual metabolites. In the case of ratios of metabolites characterised by a precursor-product 
relationship, their raw values underwent natural logarithmic transformation. Cox regression analysis. bStratified 
by recruitment center; cAdjusted for baseline fasting glucose (mg/dl) (centered on the sample mean and adding 
quadratic term), age (years), sex (male, female), intervention group (MedDiet + EVOO, MedDiet + nuts), 
body mass index (kg/m2), smoking (never, current, former), leisure-time physical activity (metabolic 
equivalent tasks in minutes/day), dyslipidemia and hypertension. False discovery rate (FDR) controlling 
adjustments were conducted by applying the method of Benjamini and Hochberg. *Homozygous carriers of the 
TCF7L2-rs7903146 T-allele.
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glucose; the mechanism has yet to be determined14, although various hypotheses, affecting regulation of the 
Wnt signalling-pathway30 have been proposed. The key effector of Wnt pathway, the bipartite transcription fac-
tor β-cat/TCF, is formed by free β-catenin (β-cat) and a TCF protein, including TCF7L231. Wnt signalling and 
TCF7L2 appear to exercise a very complex effect in metabolic homeostasis, affecting not only the pancreatic islets, 
but also other organs (liver gluconeogenesis), and crosstalk with stress, aging as well as tumorigenesis signalling 
pathways/cascades31. Several signalling components of the Wnt signal transduction pathway have been identified 
but a clear understanding of the Wnt signalling’s diverse function, integration and specificity is lacking. On the 
Figure 1. (a) Joint association of plasma xanthine levels and TCF7L2-rs7903146 genotypes in relation to type 
2 diabetes risk. The number 50 corresponds to 50th percentile; median. (b) Joint association of plasma inosine 
levels and TCF7L2-rs7903146 genotypes in relation to type 2 diabetes risk. The number 50 corresponds to 50th 
percentile; median.
Figure 2. Purine Catabolism Pathway. Reproduced and modified from41.
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other hand, there is strong evidence for a direct association between dysregulated Wnt signalling and chronic 
diseases32. In due course, choosing the rs7903146-allele, was an innovative approach in our study.
In this study, using a case-cohort design, we confirmed the association of the TCF7L2-rs7903146 TT genotype, 
with the risk of T2D in PREDIMED study participants14. Changes in the blood of TT homozygotes reported until 
now mainly concerned increased levels of plasma glucose in response to a meal challenge of proinsulin and ele-
vated glucose-dependent insulinotropic peptide secretion33; reduced secretion of insulin/glucagon, and reduced 
insulinotropic effect of incretin hormones34; altered postprandial triglyceride response, mainly influencing VLDL 
and HDL subclasses35, as well as non-significant increase of plasma sphingomyelins, phosphatidylcholines and 
lyso-phosphatidylcholines species36. To our knowledge, this is the first study to examine the interaction between 
plasma purine-catabolism metabolites levels and the TCF7L2-rs7903146 genetic variation, focusing on T2D risk.
We observed that xanthine and inosine were associated with increased T2D risk only in individuals with TT 
alleles on rs7903146. Moreover, the combination of TT genotype and high plasma xanthine and inosine levels was 
associated with a higher risk of T2D than the combined CC genotype and their low levels, which confirmed that 
both the rs7903146 T allele and increased plasma xanthine and inosine are associated with T2D. The protective 
role of inosine is well-documented37, while xanthine may simply increase due to increased XO activity in the 
blood38. A working hypothesis is that xanthine and inosine play a compensatory role, competing or cooperating; 
since in both, when their levels were low, no significant association was found between TT and T2D, as compared 
to their high levels (see joint analysis). Among purine-catabolism related ratios, only hypoxanthine-to-inosine 
ratio was inversely associated with T2D risk in individuals with TT alleles on rs7903146 with a significant test of 
interaction. Whether hypoxanthine production from inosine confers higher protection from T2D in individuals 
carrying these polymorphisms, by inhibiting the activation of poly(ADP-ribose) polymerase39 and thus increas-
ing TCF7L2-mediated GLP-1 production and activity40, needs to be further explored.
The results of the present study should be interpreted in the context of its limitations and strengths. First, 
participants were elderly Mediterranean individuals at high cardiovascular risk and this may limit the generaliz-
ability of the findings to other age-groups or populations. Second, even though we adjusted for several potential 
confounders, residual confounding may exist. Regarding strengths, the prospective evaluation of the association 
between metabolites levels and well-documented incident T2D, in the frame of a case-cohort design, minimizes 
biases that can affect case-control studies.
In conclusion, our prospective study documented, for the first time, an inverse and a positive association 
between high plasma allantoin levels, including allantoin-to-uric acid ratio and high xanthine-to-hypoxanthine 
ratio with incident T2D risk, respectively, in an elderly population at high cardiovascular risk, independently of 
the TCF7L2-rs7903146 polymorphism. Elevated plasma levels of xanthine and inosine appeared to be associated 
with higher T2D risk only in TT individuals. These results must be interpreted cautiously and need to be repli-
cated in other populations. The potential mechanisms linking the aforementioned purine metabolites and T2D 
risk must be also further investigated.
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